Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
ApexOnco Front Page
Recent articles
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
No fewer than four ADCs with this target start human testing.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company is set to start a phase 2/3 trial this month.
